SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Pharmaceuticals shines on planning to merge Cohance with itself

01 Mar 2024 Evaluate

Suven Pharmaceuticals is currently trading at Rs. 678.65, up by 47.75 points or 7.57% from its previous closing of Rs. 630.90 on the BSE.

The scrip opened at Rs. 653.95 and has touched a high and low of Rs. 712.00 and Rs. 646.00 respectively. So far 1659278 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.00 on 04-Jan-2024 and a 52 week low of Rs. 375.00 on 05-Apr-2023.

Last one week high and low of the scrip stood at Rs. 712.00 and Rs. 625.10 respectively. The current market cap of the company is Rs. 17281.14 crore.

The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 26.09% and 13.92% respectively.

Suven Pharmaceuticals has proposed scheme of amalgamation to merge Cohance Lifesciences (Cohance) with itself. This marks a pivotal moment in Suven's journey, underscoring its commitment to scaling, ensuring consistent earnings, fortifying its financial standing, and advancing towards forging leadership in the integrated CDMO space.

Cohance is a leading CDMO and Merchant API platform with global leadership in select low-mid volume molecules as well as unique capabilities in the form of its antibody drug conjugates (ADC) platform. 

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.


Cohance Lifesciences Share Price

469.95 -13.00 (-2.69%)
04-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.10
Dr. Reddys Lab 1287.95
Cipla 1334.85
Zydus Lifesciences 901.65
Lupin 2350.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×